AP662A - Anhydrous crystalline valaciclovir hydrochloride. - Google Patents

Anhydrous crystalline valaciclovir hydrochloride. Download PDF

Info

Publication number
AP662A
AP662A APAP/P/1997/001058A AP9701058A AP662A AP 662 A AP662 A AP 662A AP 9701058 A AP9701058 A AP 9701058A AP 662 A AP662 A AP 662A
Authority
AP
ARIPO
Prior art keywords
valaciclovir
hydrochloride
valaciclovir hydrochloride
crystalline
anhydrous crystalline
Prior art date
Application number
APAP/P/1997/001058A
Other languages
English (en)
Other versions
AP9701058A0 (en
Inventor
Carter Barry Howard
Partin Jane Muse
Varlashkin Peter Gregory
Winnike Richard Augustus
Grubb William Bayne
Conway Gregory Alan
Lake Philip George
Skinner David Michael
Whatrup David James
Original Assignee
The Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP662(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd
Publication of AP9701058A0 publication Critical patent/AP9701058A0/xx
Application granted granted Critical
Publication of AP662A publication Critical patent/AP662A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
APAP/P/1997/001058A 1995-01-20 1996-01-19 Anhydrous crystalline valaciclovir hydrochloride. AP662A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (2)

Publication Number Publication Date
AP9701058A0 AP9701058A0 (en) 1997-10-31
AP662A true AP662A (en) 1998-08-19

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001058A AP662A (en) 1995-01-20 1996-01-19 Anhydrous crystalline valaciclovir hydrochloride.

Country Status (40)

Country Link
US (1) US6107302A (member.php)
EP (1) EP0804436B1 (member.php)
JP (1) JP3176633B2 (member.php)
KR (1) KR100376074B1 (member.php)
CN (1) CN1049893C (member.php)
AP (1) AP662A (member.php)
AR (1) AR002270A1 (member.php)
AT (1) ATE302777T1 (member.php)
AU (1) AU702794B2 (member.php)
BG (1) BG63393B1 (member.php)
BR (1) BR9606768A (member.php)
CA (1) CA2210799C (member.php)
CY (1) CY2531B1 (member.php)
CZ (1) CZ297065B6 (member.php)
DE (1) DE69635106T2 (member.php)
DK (1) DK0804436T3 (member.php)
EA (1) EA000364B1 (member.php)
EE (1) EE03528B1 (member.php)
ES (1) ES2248806T3 (member.php)
FI (1) FI973063L (member.php)
GB (1) GB9501178D0 (member.php)
GE (1) GEP20001940B (member.php)
HR (1) HRP960024B1 (member.php)
HU (1) HU222993B1 (member.php)
IL (1) IL116831A (member.php)
IN (1) IN182468B (member.php)
IS (1) IS2268B (member.php)
NO (1) NO315558B1 (member.php)
NZ (1) NZ298851A (member.php)
OA (1) OA10499A (member.php)
PL (1) PL182175B1 (member.php)
RO (1) RO118693B1 (member.php)
RS (1) RS49518B (member.php)
SI (1) SI0804436T1 (member.php)
SK (1) SK285329B6 (member.php)
TR (1) TR199700656T1 (member.php)
UA (1) UA46001C2 (member.php)
UY (1) UY25779A1 (member.php)
WO (1) WO1996022291A1 (member.php)
ZA (1) ZA96449B (member.php)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
ES2210490T3 (es) * 1996-01-19 2004-07-01 Glaxo Group Limited Uso de valaciclovir para la fabricacion de un medicamento para el tratamiento del herpes genital por una unica administracion diaria.
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
CA2278474A1 (en) * 1997-01-17 1998-07-23 Ajinomoto Co., Inc. Novel z-valacyclovir crystals
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
HRPK20110926B3 (hr) * 2001-02-24 2013-05-31 Boehringer Ingelheim Pharma Gmbh & Co.Kg. Derivati ksantina, njihova proizvodnja i upotreba kao lijekova
CZ2004446A3 (cs) * 2001-09-07 2005-01-12 Teva Pharmaceutical Industries Ltd. Krystalické formy valaciklovir hydrochloridu
AU2002348022B2 (en) * 2001-11-05 2006-06-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
KR20070020149A (ko) * 2001-11-14 2007-02-16 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르의 합성 및 정제 방법
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
AU2003277433A1 (en) * 2002-10-16 2004-05-04 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AU2003232719A1 (en) 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
CA2527708A1 (en) 2003-06-02 2005-01-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
JP2007522130A (ja) * 2004-01-21 2007-08-09 テバ ファーマシューティカル インダストリーズ リミティド 塩酸バラシクロビルの調製方法
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP1761535A1 (en) * 2004-06-30 2007-03-14 Teva Pharmaceutical Industries Ltd Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
WO2006127217A2 (en) * 2005-05-25 2006-11-30 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
CA2873524C (en) 2006-05-04 2018-02-20 Boehringer Ingelheim International Gmbh A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
CN101784278A (zh) * 2007-08-17 2010-07-21 贝林格尔.英格海姆国际有限公司 用于治疗fab-相关的疾病的嘌呤衍生物
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
MX370599B (es) * 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX2011006713A (es) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Formas salinas de compuesto organico.
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
MX364651B (es) 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US20140296520A1 (en) * 2011-11-25 2014-10-02 Piramal Enterprises Limited Process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029311A1 (en) * 1993-06-10 1994-12-22 Farmhispania Sa Amino acid ester of nucleoside analogues
EP0308065B1 (en) * 1987-08-15 1995-01-04 The Wellcome Foundation Limited Therapeutic nucleosides
WO1996022291A1 (en) * 1995-01-20 1996-07-25 The Wellcome Foundation Limited Guanine derivative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308065B1 (en) * 1987-08-15 1995-01-04 The Wellcome Foundation Limited Therapeutic nucleosides
EP0596542B1 (en) * 1987-08-15 1996-05-29 The Wellcome Foundation Limited Therapeutic nucleosides
WO1994029311A1 (en) * 1993-06-10 1994-12-22 Farmhispania Sa Amino acid ester of nucleoside analogues
WO1996022291A1 (en) * 1995-01-20 1996-07-25 The Wellcome Foundation Limited Guanine derivative

Also Published As

Publication number Publication date
US6107302A (en) 2000-08-22
IS2268B (is) 2007-07-15
EE9700175A (et) 1998-02-16
HU222993B1 (hu) 2004-01-28
GEP20001940B (en) 2000-02-05
OA10499A (en) 2002-04-10
EP0804436B1 (en) 2005-08-24
AP9701058A0 (en) 1997-10-31
CN1179159A (zh) 1998-04-15
CY2531B1 (en) 2006-04-12
FI973063A7 (fi) 1997-09-18
NZ298851A (en) 1999-01-28
RO118693B1 (ro) 2003-09-30
ATE302777T1 (de) 2005-09-15
EE03528B1 (et) 2001-10-15
AR002270A1 (es) 1998-03-11
TR199700656T1 (xx) 1998-03-21
NO973326D0 (no) 1997-07-18
KR19980701525A (ko) 1998-05-15
HUP9801836A3 (en) 1999-06-28
PL321326A1 (en) 1997-12-08
SK96597A3 (en) 1998-02-04
IL116831A0 (en) 1996-05-14
FI973063L (fi) 1997-09-18
EA199700124A1 (ru) 1997-12-30
DK0804436T3 (da) 2005-12-27
ES2248806T3 (es) 2006-03-16
CA2210799C (en) 2008-06-10
HRP960024B1 (en) 2005-08-31
CZ229497A3 (en) 1997-12-17
DE69635106D1 (de) 2005-09-29
EP0804436A1 (en) 1997-11-05
BG101833A (bg) 1998-04-30
FI973063A0 (fi) 1997-07-18
UA46001C2 (uk) 2002-05-15
BR9606768A (pt) 1997-12-30
HRP960024A2 (en) 1997-10-31
IS4527A (is) 1997-07-15
IL116831A (en) 1998-10-30
HUP9801836A2 (hu) 1999-05-28
SK285329B6 (sk) 2006-11-03
GB9501178D0 (en) 1995-03-08
KR100376074B1 (ko) 2003-06-02
WO1996022291A1 (en) 1996-07-25
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
AU4453996A (en) 1996-08-07
EA000364B1 (ru) 1999-06-24
SI0804436T1 (sl) 2006-02-28
UY25779A1 (es) 2000-08-21
NO973326L (no) 1997-09-16
RS49518B (sr) 2006-10-27
DE69635106T2 (de) 2006-06-08
CA2210799A1 (en) 1996-07-25
JPH11503718A (ja) 1999-03-30
NO315558B1 (no) 2003-09-22
YU3396A (sh) 1998-12-23
ZA96449B (en) 1996-08-07
IN182468B (member.php) 1999-04-17
MX9705462A (es) 1997-10-31
CZ297065B6 (cs) 2006-08-16
JP3176633B2 (ja) 2001-06-18
AU702794B2 (en) 1999-03-04
PL182175B1 (pl) 2001-11-30

Similar Documents

Publication Publication Date Title
AP662A (en) Anhydrous crystalline valaciclovir hydrochloride.
KR100412298B1 (ko) 콜로이드이산화규소를함유하는발라시클로비르정제
CA2243237C (en) Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
HK1003055A1 (en) Guanine derivative
HK1003055B (en) Guanine derivative
MXPA97005462A (en) Derived from guan
MXPA97005459A (en) Valaciclovir tablets containing silicon dioxide color